Scribe Therapeutics

Scribe Therapeutics Inc. (Nasdaq: SCTX) is a clinical-stage biotechnology company based in Alameda, California, that engineers purpose-built in vivo CRISPR technologies designed to extend healthy lifespan through disease prevention and durable therapeutic intervention. Founded with Nobel Prize-winning science by CRISPR pioneers from UC Berkeley, the company uses molecular engineering to modify natural CRISPR systems into specific and potent therapies, and is designing a portfolio of treatments for cardiometabolic disease. Its pipeline includes STX-1150, a novel LDL-C lowering therapy powered by ELXR epigenetic silencing technology, as well as STX-1200 for Lp(a) lowering and STX-1400 for triglyceride lowering. The company pursues strategic collaborations with pharmaceutical companies to broaden its molecular engineering approach to other therapeutic areas.

Scribe Therapeutics was founded by CRISPR pioneers from UC Berkeley, including Jennifer A. Doudna, PhD, who serves as Co-founder and Scientific Advisor. The company was founded with Nobel Prize-winning science and works to maximize human health with safe, effective genetic medicines for everyone. It accomplishes this through molecular engineering, taking natural CRISPR systems and comprehensively modifying them into the most specific and potent therapies possible. The company is designing a portfolio of treatments for cardiometabolic disease. In 2026, Scribe Therapeutics Inc. (Nasdaq: SCTX) reported second quarter financial results and recent corporate highlights, including initiating the first-in-human Phase 1 trial of STX-1150, a novel LDL-C lowering therapy powered by ELXR epigenetic silencing technology; being awarded more than $25 million from the California Institute for Regenerative Medicine (CIRM) to advance STX-1200 for Lp(a) lowering and STX-1400 for triglyceride lowering toward clinical entry; and completing an upsized initial public offering, including full exercise of the underwriters' purchase option, and a concurrent private placement to Sanofi, generating approximately $155.5 million in aggregate gross proceeds.

Engineering purpose-built in vivo CRISPR technologies designed to extend healthy lifespan through disease prevention and durable therapeutic intervention.

• STX-1150

  A novel LDL-C lowering therapy powered by ELXR, a highly engineered epigenetic silencing technology designed to deliver ultra-long-acting cholesterol lowering without permanent genetic changes.

• STX-1200

  A therapy for Lp(a) lowering.

• STX-1400

  A therapy for triglyceride lowering.

1. 1Scribescribetx.com
2. 2Scribe → Aboutscribetx.com
3. 3Scribe → Scribe Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlightsscribetx.com
4. 4Scribe Therapeuticswikidata.org
5. 5Scribe Therapeutics launches a platform for engineering CRISPR-based therapeutics | TechCrunchtechcrunch.com